Collaborations
Antibody Characterization
MedImmune
MedImmune and ProGenosis have collaborated to elucidate a complex epitope on the extracellular domains of CD22, a specific marker on the surface of malignant B cells, in its interaction with an immunotoxin, currently in clinical development for the treatment of lymphocytic and lymphoblastic leukemias. The study, carried out using the BHP technology, showed that the interaction with the anti-CD22 antibody is indeed complex and involves at least 3 discontinuous regions of the CD22 polypeptide.
bioMérieux
bioMérieux and ProGenosis have collaborated on various undisclosed R&D projects.
Biotie Therapies
Biotie Therapies and ProGenosis have collaborated to identify the conformation-dependent epitope upon an undisclosed target
ID VET
IDVET and ProGenosis have combined their efforts on the mapping of an undisclosed viral target.
Antibody Development
Folia Biotech
Folia and ProGenosis have joined their competencies to develop viral antigen for vaccination purposes.
Protein Expression
D-tek
D-tek and Progenosis have combined their know-how to develop and produce new target antigens for in vitro diagnostic applications